GLP-1 Pill vs Injection: What Really Changes for Patients in 2026
The biggest change is simple: pills are no longer a side story. In the US, Eli Lilly’s Foundayo, the brand name for orforglipron, was approved by the FDA on April 1, 2026 as a GLP-1 pill for chronic weight management. Reuters also reported that Novo Nordisk had already launched an oral Wegovy option earlier in … Read more